Track topics on Twitter Track topics that are important to you
Axcella Health Inc. (therapies addressing dysregulated metabolism) netted $66.4mm in its initial public offering of 3.57mm common shares at $20 each, the low end of its anticipated range.
Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism and support health, today annou...
Shreeram Aradhye has been appointed executive vice president and chief development officer of Axcella Health. Aradhye was most recently chief medical officer and global head of medical affairs for Nov...
Axcella is designing and developing novel endogenous metabolic modulator compositions to safely reprogram metabolic dysregulation. We are transforming the discovery and developmen...
We have published hundreds of Axcella news stories on BioPortfolio along with dozens of Axcella Clinical Trials and PubMed Articles about Axcella for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Axcella Companies in our database. You can also find out about relevant Axcella Drugs and Medications on this site too.